Diabetes imposes a substantial burden on societies worldwide: approximately 25 million individuals in the US have diabetes, of which more than 95 % is type 2.
with an increased risk for hospitalizations for heart failure. 12 Studies investigating the CV risks associated with insulin, sulfonylureas (SU), and metformin have yielded mixed results. 13, 14 Since over 85 % of people with diabetes are overweight or obese, 15 and excess weight is a major contributor to the development of insulin resistance and impaired glucose tolerance, 16 as well as being a major CV risk, 17 the impact of antidiabetic therapies on weight is also important. Most oral antidiabetic agents (OADs) have been associated either with weight gain (thiazolidinediones, 18 SU, 19 meglitinides 20 ) or are weight-neutral (metformin, 21 alpha-glucosidase inhibitors, 22 DPP-4 inhibitors, 23 bile acid sequestrants 24 ).
Treatment with insulin and insulin analogs is also associated with weight gain, which may be substantial. 25 GLP-1 analogs have been associated with moderate weight loss, 10 but their use is limited by the need for administration by injection and gastrointestinal side effects. 26 The increasing prevalence of type 2 diabetes, in combination with limitations of current therapies, has driven the search for alternative glucose-lowering agents. This review will consider the safety and efficacy of a new class of oral drug, sodium glucose co-transporter 2 (SGLT2) inhibitors and the key clinical trial evidence supporting their use in diabetes treatment.
Introduction to Sodium Glucose Co-transporter 2 Inhibitors
A new therapeutic approach to type 2 diabetes has emerged using SGLT2
inhibitors, whose mechanism of action is independent of insulin and involves glucose reabsorption in the kidneys. The kidneys play an important role in glycemic control, filtering, and reabsorbing glucose back into the circulatory system. 27 Renal glucose transport involves two types of membrane-associated carrier proteins: facilitated glucose transporters (GLUTs), which function as passive transporters, and sodium glucose co-transporters (SGLTs), which are secondary active co-transporters. 27, 28 Among the latter, SGLT2s, found in the early proximal tubule, are responsible for approximately 90 % of glucose reabsorption. 27, 29 In type 2 diabetes, SGLT2 is upregulated, resulting in reduced glucosuria and hyperglycemia, suggesting that an adaptive response to conserve glucose becomes maladaptive in diabetes. 28 The concept of inhibiting glucose reabsorption arose from the discovery of inherited and acquired diseases in which SGLT2 mutations cause alterations in renal glucose handling, resulting in glucosuria. 30 Selective SGLT2 inhibitors decrease glucose reabsorption in the kidneys, increasing urinary glucose excretion. Such agents may offer several advantages as antidiabetic agents: the unique potential to cause negative energy balance and the correction of the effect of hyperglycemia on insulin secretion and action. 31, 32 The use of SGLT2 inhibitors will, however, require a change in the perception of glucosuria. This has historically been considered to indicate poor glucose control but during SGLT2 inhibitor treatment it indicates effective removal of excess glucose from the blood to the urine. 33 Phlorizin, discovered in 1835, was the first SGLT inhibitor, but is not suitable for clinical use owing to its poor bioavailability and gastrointestinal side effects, a result of its action on SGLT1, found mainly in the small intestine. 
Effects on Cardiovascular Risk Factors of Sodium Glucose Co-transporter 2 Inhibitors
Several large clinical trials assessing the CV safety of SGLT2 inhibitors are ongoing (see Table 5 ). The most comprehensive data currently available are from a meta-analysis of data from 14 phase II/III studies involving 6, 228 patients that assessed the CV safety of all doses of dapagliflozin (2.5 to >10 mg). The primary end point was a composite of time to first event of CV death, myocardial infarction (MI), stroke, or hospitalization for unstable angina. The estimated hazard ratio (HR) was 0.674 (95 % CI 0.421-1.078),
suggesting that dapagliflozin was not associated with an increased risk for CV events and may confer a reduced CV risk. 65 The 
Blood Pressure
The importance of tight BP control in patients with type 2 diabetes is well established. In the UK Prospective Diabetes Study (UKPDS), patients assigned to the tight BP control arm had a clinically meaningful reduction in the risk for deaths related to diabetes and its related complications. 67 Since SGLT2 reabsorbs glucose and sodium in the renal proximal tubule, it was postulated that SGLT2 inhibitors would have diuretic properties, thereby reducing BP. In phase III studies, dapagliflozin has been associated with reductions of systolic BP at week 24 of -3.6, -5.1, and -5.0 mmHg as monotherapy, 39 add-on to metformin, 38 and add-on to SU, 41 respectively. In a recent clinical study, 75 subjects were randomized to placebo, dapagliflozin, or hydrochlorothiazide (HCTZ), a diuretic used in the treatment of hypertension. Treatment with placebo or HCTZ resulted in changes from baseline in 24-hour ambulatory mean systolic BP of -0.9, -3.3, and -6.6 mmHg, respectively, at week 12, adjusted for baseline systolic BP. Plasma volume appeared to decrease with dapagliflozin but did not change with placebo or HCTZ treatment, suggesting that dapagliflozin has a diuretic-like capacity to lower BP. 68 Canagliflozin has been associated with similar reductions in systolic BP (at week 24, -3.7 mmHg -5.4 mmHg from placebo with 100 mg and 300 mg doses, respectively, p≤0.001). 44 Empagliflozin has also been found to have beneficial effects on BP. In a recent pooled analysis of data from four phase III trials, at week 24, patients given empagliflozin 10 mg and 25 mg showed reductions in systolic BP of 3.9 mmHg and 4.3 mmHg, and diastolic BP of 1.8 mmHg and 2.0 mmHg, respectively, compared with reductions of 0.5 mmHg in systolic BP and 0.6 mmHg in diastolic BP in patients treated with placebo (see Figure 1) . 55 Empagliflozin treatment resulted in generally greater reductions in BP when baseline BP was higher. increases in high-density lipoprotein-cholesterol (HDL-C) have been reported but also increases in LDL-C. 69 In a pooled analysis of data from 3,731 patients in 12 phase IIb/phase III trials of dapagliflozin, changes from baseline in HDL-C were +6.5 % and +5.5 % for dapagliflozin 5 and 10 mg, respectively, versus +3.8 % placebo, and in LDL-C +0.6 % and +2.7 % dapagliflozin 5 and 10 mg, respectively, versus -0.4 % placebo. 70 Pooled data from four phase III trials investigating empagliflozin found small changes from baseline in LDL-C of +3.1 mg/dl and +3.9 mg/dl for empagliflozin 10 mg and 25 mg, respectively, compared with +0.8 mg/dl for placebo. Changes from baseline in HDL-C were +2.7 mg/dl for both doses versus 0.0 mg/dl for placebo. Changes from baseline in triglyceride levels of -9.7 mg/dl and -1.8 mg/dl, respectively, compared with +2.7 mg/dl for placebo. 55 The significance of the increased LDL-C with SGLT2 inhibitors requires further investigation.
In some clinical trials of SGLT2 inhibitors, plasma lipid analysis has been conducted using nuclear magnetic resonance (NMR) spectroscopy. This trial. 47 The trial compared canagliflozin 100 mg and 300 mg treatment with placebo over a 26-week randomized period in patients with type 2 diabetes and inadequate glycemic control on metformin monotherapy. Increased cholesterol levels are a concern with these treatments and NMR analysis of plasma at baseline and week 26 showed slightly greater increases in LDL particle concentrations in patients treated with either canagliflozin doses compared with placebo. This pattern of increased LDL particle concentrations with canagliflozin was similar for both large and small LDL particles but there was little difference between the two cangliflozin doses in LDL particle concentrations. In the CANagliflozin Treatment and
Trial Analysis -Monotherapy (CANTATA-M) trial, NMR spectroscopy showed small increases in Apo B levels during 26 weeks of treatment of type 2 diabetes patients insufficiently controlled with diet and exercise. 71 In placebo-treated patients Apo B levels were shown to decrease by 0.2 % but in 100 mg and 300 mg cangliflozin-treated patients these levels rose by 1.3 % and 3.2 %, respectively.
Body Weight
Other benefits of SGLT2 inhibitors include clinically meaningful body weight reduction, which give a strong rationale for their use in overweight and obese patients, as well as in addition to therapies that are associated with weight gain. The glycosuria induced by dapagliflozin monotherapy is associated with a net calorie loss of approximately 200-300 kilocalories per day. 72 In phase III studies, dapagliflozin has been associated with adjusted mean change from baseline in body weight at 24 weeks of -3.2 kg as monotherapy, 39 -2.9 kg as add-on to metformin, 38 -2.26 kg as add-on to SU, 41 and -1.61 kg as addon to insulin. 42 Pooled analysis of four clinical trials showed that the use of 55 canagliflozin was associated with weight loss ranging from 0.7 to 3.5 kg at 24 weeks. 44 In a pooled analysis of four phase III trials, empagliflozin was associated with weight losses of 2.05 kg and 2.25 kg, respectively, from baseline at 24
weeks, compared with a reduction of 0.24 kg for placebo (see Figure 2) . 55 Since a proportion of the weight reduction observed with SGLT2s is related to reduction in visceral fat mass, this could potentially be important for CV risk reduction.
Safety of Sodium Glucose Co-transporter 2 Inhibitors
Hypoglycemia is a rare adverse event (AE) during SGLT2 inhibitor therapy. 73 In an analysis from the CANagliflozin cardioVascular Assessment Study (CANVAS) study, hypoglycemic AEs were higher with canagliflozin compared with placebo only in patients taking concomitant insulin, SU, or meglitinide. 74 In the pooled analysis of empagliflozin trials, hypoglycemic AEs were reported by 2. The rates of serious UTIs or UTIs leading to therapy discontinuation were not significantly different in the two groups. 75 In a pooled analysis from 2,477 patients participating in phase III empagliflozin trials, the rates of UTI were not statistically different (8.2 %, 9.3 %, and 7.5 %) in the placebo, lower-dose, and higher-dose groups, respectively. 76 Clinical trial data indicate that infections are typically mild in nature, may be circumvented with rigorous hygiene, respond well to treatment, and are unlikely to lead to discontinuation of the drug.
Dapagliflozin has been associated with a mean increase in daily urine output of 107-375 ml/day secondary to a mild osmotic diuresis. 77 Study populations received counseling about symptoms of dehydration and the importance of adequate fluid consumption, and this has proven effective.
One patient in a phase II study with dapagliflozin developed dehydration and renal impairment, which resolved with oral rehydration and withholding angiotensin-converting enzyme (ACE) inhibitor and diuretic treatment. 78 While further research is required to ascertain the long-term safety of these effects in patients taking SGLT2 inhibitors, patients with autosomal recessive renal glucosuria resulting from a mutation in the SGLT2 have not reported clinical complications resulting from chronic elevated urinary glucose, and the condition is considered benign. 
Future Developments in Sodium Glucose Co-transporter 2 Inhibitor Treatments
A projection for 20 years based on a population simulation model (Archimedes) that includes National Health and Nutrition Examination Survey (NHANES) study data showed that patients receiving dapagliflozin were likely to experience reductions in the incidence of MI, stroke, CV death, and all-cause death of 13.8 %, 9.1 %, 9.6 %, and 5.0 %, respectively.
In addition, there would be relative reductions in the incidence of end-stage renal disease, foot amputation, and diabetic retinopathy of 18.7 %, 13.0 %, and 9.8 %, respectively, compared with the current standard of care. 85 Additional and larger phase III clinical trials to fully define the potential role of canagliflozin and other SGLT2 inhibitors in the management of diabetes, including studies involving the elderly, children, and patients with renal or hepatic dysfunction, are planned or currently ongoing.
The diuretic effect observed with SGLT2 inhibitors may make them the preferred class of drugs to be used in conjunction with thiazolidinediones, which have been shown to cause fluid retention, especially in the presence of heart failure. However, since most antidiabetic agents have been associated with increased risk for all-cause mortality in patients with heart failure and diabetes, 86 future trials should add heart failure as part of the primary endpoint.
SGLT2 inhibitors also offer potential in the treatment of type 1 diabetes.
In a phase IIa trial in type I diabetes, patients taking dapagliflozin had improved glycemic control and required less insulin than those on placebo. 87 In a pilot proof-of-concept trial in type 1 diabetes, empagliflozin as adjunct to insulin therapy improved glycemic control while reducing insulin requirement, weight, and episodes of hypoglycemia. 88 Individuals with type 1 diabetes are at high risk for the development of hypertension, for which hyperglycemia-mediated neurohormonal activation is an important contributing factor. Mechanistic trials in type 1 diabetes indicate that empagliflozin causes an improvement in arterial stiffness and reduction in renal hyperfiltration.
89,90
Summary and Concluding Remarks Given the ever-expanding incidence of diabetes in populations worldwide and suboptimal glycemic control achieved with currently available agents, the need for novel agents, with new modes of action remains an urgent clinical and public health priority. SGLT2 inhibitors are a useful addition to the treatment armamentarium. n
